US Politicians Are Buying These Two Stocks

Recent filings from American politicians reveal an increase in purchases of two specific stocks: Accenture (NYSE: ACN) and Boston Scientific (NYSE: BSX). Congressman Gilbert Ray Cisneros, Jr. (D-CA) acquired shares of Boston Scientific on August 18, 2026, while Rep. Ro Khanna (D-CA) made two purchases of the stock, on August 3 and August 10, 2026, according to a filing dated September 4, 2026.

Neither politician sold their Boston Scientific shares during this period. Additionally, both Cisneros and Khanna were among the buyers of Accenture shares in July and August. This information is derived from Quiver Quantitative, a platform that tracks congressional stock trades. Boston Scientific's (BSX) stock has declined by approximately 50% this year due to a cyberattack that disrupted manufacturing, order processing, and shipments, leading to the company withdrawing its previous financial outlook.

Business analysts argue that the market has already priced in an excessively severe outcome, as BSX's major distribution centers are now shipping at or above normal levels, sterilization facilities are operational, and production has resumed at most plants. Despite the disruption, the company's revenue for the second quarter grew by 7.5% year-over-year, with organic growth at 7%.

Core franchises such as Interventional Cardiology and Vascular Therapies, Interventional Oncology and Embolization, and Neuromodulation contributed to double-digit organic growth. Conversely, critics contend that Boston Scientific's business experienced a pre-existing slowdown. Sales growth for WATCHMAN, a heart implant that reduces stroke risk in individuals with irregular heartbeats, and BSX's heart-rhythm treatment business in the US significantly slowed due to competition.

There are concerns that the company may lose some customers to rivals following the cyberattack, while its acquisition of Penumbra introduces debt that could negatively impact earnings in the first year. BSX's current valuation stands at 13.07 times forward non-GAAP earnings, which is about 30.64% below the healthcare-sector median of 18.85 times.

Additionally, its trailing non-GAAP P/E ratio of 13.39 times is 26.61% lower than the sector median. Some investors believe the market undervalues BSX, considering it a damaged business despite sustained growth, strong margins, and substantial cash generation.